Translational Development for Protein Therapeutics

Albrem is a translational and product development organization (Pre-CRO) dedicated to de-risking and advancing protein therapeutics and vaccines. We bridge the gap between discovery and IND-enabling studies through rigorous protein engineering, optimization, analytical and formulation studies, and strategic development planning. We operate in the critical stage between early discovery and development, where promising protein candidates can benefit from being appropriately engineered, optimized, characterized, formulated, and strategically positioned before entering clinical studies.

At Albrem we combine rapid, focused protein engineering and optimization services to reach decision-grade candidate readiness. We combine structure and sequence-informed AI variant design (AI/ML sequence information for directed changes) with wet-lab validation to deliver soluble, functional, and developable candidates ready for the next stage of development and advancement to manufacturing. This is accomplished with state-of-the-art analytical equipment, rigorous assay designs and reproducible performance.

We go beyond to deliver a translational development data package that includes candidate screening, developability assessment, optimization and strategic recommendations, so you have the protein, analytics, and decision-grade data you need to proceed with confidence in candidate selection and manufacturing.

Albrem Scientist

Our Mission

To de-risk the transition from discovery to clinical development through rigorous protein engineering, characterization and translational strategy. We help transform early scientific promise into a development-ready therapeutic candidate.

What Albrem Is

Albrem is not a traditional CRO. We are positioned earlier in the process, in the "bench-to-clinic" transition phase.

  • We focus on: Candidate engineering, expression system strategy (cell-free, E. coli, CHO), analytical characterization, stability assessment, and early formulation.
  • We do not conduct: GLP toxicology, GMP manufacturing, or clinical trial execution.

Once a program is technically and strategically prepared, it can transition into structured regulatory development through established CRO partners.

Who We Work With

Our clients are typically venture-backed biotech startups, academic spinouts, and strategic pharma innovation teams. We work directly with CEOs, CSOs, and translational leads who:

  • Have identified a promising therapeutic protein with early biological validation.
  • Need stronger data before fundraising, partnership, or animal studies.
  • Want to reduce technical risk before significant pre-IND and clinical investment.

Bridging the "Valley of Death"

Drug development is high risk. Many programs fail not because the biology is wrong—but because the protein was never fully optimized for development. Common failure points include:

  • Poor affinity, expression, instability, or aggregation.
  • Insufficient analytical characterization.
  • Weak early formulation strategy.
  • Data packages that lack translational rigor.

Albrem acts as the bridge, reducing uncertainty before large-scale investment.

Our Translational Approach

We apply a structured, iterative framework inspired by Design–Build–Test–Learn (DBTL), integrating molecular biology, protein engineering, biochemistry, and analytical science with early regulatory awareness.

  1. Rational Construct Design: Guided by computational and structural insight.
  2. Iterative Engineering: Selection and refinement of protein candidates.
  3. High-Resolution Validation: Rigorous expression and analytical testing to confirm developability.
  4. Strategic Alignment: Ensuring laboratory insight meets clinical intent.

Areas of Scientific Focus

Albrem specializes in advanced biologics and engineered protein modalities:

  • Monoclonal antibodies and Fc-fusion proteins.
  • Recombinant enzymes and antigen constructs.
  • Multi-antibody or multi-protein systems.
  • Special Interests: Neural targets (BBB challenges), intranasal delivery, and precision medicine or ADC strategies.

Albrem at a Glance

  • Type: Translational Development Organization (Pre-CRO)
  • Focus: Engineered protein therapeutics
  • Stage: Bench to early clinical transition
  • Core Value: Scientific de-risking and rational optimization, ensuring your development path is aligned with future reality
  • Outcome: Development-ready protein candidates

Engineering discipline is the difference between promise and progress.

We welcome the opportunity to collaborate with you on the development of custom proteins tailored to your specific needs.

For more information about services and support opportunities with Albrem Biopharma please contact us.

Contact Us